QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.105.004283v1 33/10/1503    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gschwind, H.-P. Articles by Gross, G. Search for Related Content PubMed PubMed Citation Articles by Gschwind, H.-P. Articles by Gross, G.

METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

Novartis Pharma AG, Exploratory Development/Drug Metabolism & Pharmacokinetics, Basel, Switzerland (H.-P.G., U.P., F.W., M.Z., C.S., P.Z., G.G.); Novartis Pharmaceuticals Corporation, Exploratory Development/Bioanalytics & Pharmacokinetics (M.H.), Clinical Pharmacology Oncology (M.B.-A., B.P.), East Hanover, New Jersey; and Swiss Pharma Contract, Clinical Pharmacology & Clinical Research, Allschwil, Switzerland (R.P., M.S.)

(Received February 22, 2005; accepted July 6, 2005)

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male healthy volunteers after a single oral dose of 239 mg of ¹⁴C-labeled imatinib mesylate. Biological fluids were analyzed for total radioactivity, imatinib, and its main metabolite CGP74588. Metabolite patterns were determined by radio-high-performance liquid chromatography with off-line microplate solid scintillation counting and characterized by liquid chromatography-mass spectrometry. Imatinib treatment was well tolerated without serious adverse events. Absorption was rapid (t_max 1-2 h) and complete with imatinib as the major radioactive compound in plasma. Maximum plasma concentrations were 0.921 ± 0.095 µg/ml (mean ± S.D., n = 4) for imatinib and 0.115 ± 0.026 µg/ml for the pharmacologically active N-desmethyl metabolite (CGP74588). Mean plasma terminal elimination half-lives were 13.5 ± 0.9 h for imatinib, 20.6 ± 1.7 h for CGP74588, and 57.3 ± 12.5 h for ¹⁴C radioactivity. Imatinib was predominantly cleared through oxidative metabolism. Approximately 65 and 9% of total systemic exposure [AUC_{0-24 h} (area under the concentration time curve) of radioactivity] corresponded to imatinib and CGP74588, respectively. The remaining proportion corresponded mainly to oxidized derivatives of imatinib and CGP74588. Imatinib and its metabolites were excreted predominantly via the biliary-fecal route. Excretion of radioactivity was slow with a mean radiocarbon recovery of 80% within 7 days (67% in feces, 13% in urine). Approximately 28 and 13% of the dose in the excreta corresponded to imatinib and CGP74588, respectively.

The pathogenesis of chronic myelogenous leukemia (CML) has been attributed to the expression of the BCR-ABL fusion oncogene formed by an aberrant chromosomal translocation that generates the Philadelphia chromosome (Deininger et al., 2003). Gain-of-function mutations of KIT receptor tyrosine kinases and PDGFRs have been associated with gastrointestinal stromal tumors (GIST) (Hirota et al., 1998; Rubin et al., 2001; Dagher et al., 2002). Imatinib is also indicated for treatment of metastatic and unresectable malignant GIST (Demetri et al., 2002). Imatinib is now the first-line therapy for all phases of CML and GIST (O'Brien et al., 2003a).

Expansion of the clinical applications of imatinib is anticipated. Dysregulated PDGFR kinase activity has been linked to a variety of cancers, including glioblastoma, dermatofibrosarcoma protuberans, idiopathic hypereosinophilic syndrome, as well as other myeloproliferative diseases (Tuveson and Fletcher, 2001; le Coutre et al., 2004). In addition, imatinib has also been shown, in animal models, to enhance the antitumor effects of chemotherapeutic agents due to inhibition of ß-PDGFR (Pietras et al., 2002) and therefore may have potential efficacy as an adjuvant therapy.

The purpose of this study was to investigate the disposition and biotransformation of imatinib mesylate in healthy volunteers as part of the clinical development of the compound. Whereas previous studies have reported on pharmacokinetic and pharmacodynamic properties as well as the overall tolerability and safety of imatinib in the plasma of CML patients (Peng et al., 2004b; Schmidli et al., 2005) and healthy volunteers (Nikolova et al., 2004), the data presented here include the complete characterization of the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [¹⁴C]imatinib administration to healthy volunteers.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

 
Reference Compounds and Other Materials. The following nonradiolabeled reference compounds were synthesized by Oncology Research, Chemistry Department, Novartis Pharma AG (Basel, Switzerland): CGP74588, CGP72383, CGP71422, AFN911, APG050, and APG049. The purity of the reference compounds was separately examined by LC-MS. Solvents and reagents, all of analytical grade, were purchased from commercial manufacturers.

Subjects. This study enrolled four healthy male Caucasian volunteers, age 41 to 55 years, with medium body frame and weight (range from 61.8 to 85.7 kg). The subjects were genotyped with respect to hepatic cytochrome P450 isoenzyme CYP2D6.

Drug Administration. After a 10-h fast, each subject received a single oral dose of a nominal 239 mg of [¹⁴C]imatinib mesylate corresponding to 200 mg of imatinib free base. The actual dose (mean ± S.D., n = 4) administered was 237.0 ± 3.6 mg of [¹⁴C]imatinib mesylate (=198.4 ± 3.0 mg of free base) given in a hard gelatin capsule. The radioactive dose given per subject was 1.18 MBq (31.9 µCi).

¹⁴C-Radiolabeled Imatinib. The radiolabeled drug [¹⁴C]imatinib mesylate was synthesized by the Isotope Laboratory of Novartis Pharma AG. It was purified by chromatography, blended by recrystallization with nonradiolabeled drug substance using a nonradiolabeled Good Manufacturing Practice batch released for human use, and analyzed for release for human use according to predefined specifications. Radiochemical purity was 100% with a specific radioactivity of 4.99 kBq/mg [¹⁴C]imatinib salt (135 nCi/mg).

Radiation Protection. Radiation dosimetry calculations and the study protocol were approved by the Swiss National Radiation Protection Authority. Calculations were performed according to the rules of International Commission on Radiological Protection. Retrospective examination confirmed that the whole body dose (effective dose) was clearly below 1 mSv. The written informed consent was obtained from the subjects before enrolment.

Sample Collection. All blood samples were taken by either direct venipuncture or an indwelling cannula inserted into a forearm vein. Plasma was separated by centrifugation. A blank urine sample (250 ml) was collected the day before dose administration, and urine and feces were collected completely after dose administration. The subjects were confined to the clinical premises during the sampling period. They had access only to toilets specially equipped for complete collection of excreta.

Sample Storage and Shipment Conditions. After sample collection, blood, plasma, urine, and feces samples were kept refrigerated at 4 to 8°C. The samples were then stored frozen at -18°C until and after analysis in the analytical laboratories. Stability of imatinib and its metabolites was ascertained under these conditions (Bakhtiar et al., 2002). Samples were shipped to other analytical laboratories under dry ice.

Analysis of Unchanged Imatinib and Its Main Metabolite CGP74588. Concentrations of imatinib and its major metabolite (CGP74588) in all plasma samples of each individual subject were quantified by a validated specific assay based on LC-MS (Bakhtiar et al., 2002).

Radioactivity Analysis of Blood, Plasma, Urine, and Feces Samples. Determination of ¹⁴C radioactivity in blood, plasma, and urine samples (three replicates per time point) was performed using a Tri-Carb 2000 CA or TR 2500 liquid scintillation counter (LSC) (PerkinElmer Life and Analytical Sciences, Boston, MA). Feces samples (four replicates) were combusted in a PerkinElmer A307 oxidizer (PerkinElmer Life and Analytical Sciences), and the ¹⁴CO₂ produced was trapped into the alkaline scintillation cocktail (Carbo-Sorb; PerkinElmer Life and Analytical Sciences); radioactivity was measured by means of LSC. Urine and plasma samples were measured directly after the addition of LSC cocktail using standard counting procedures, and quench correction was performed by an external standard method (Botta et al., 1985). Radioactivity determination in pooled feces homogenates as well as residual pellets from extractions for metabolism investigations was performed after solubilization with Soluene 350 (PerkinElmer Life and Analytical Sciences) and the addition of liquid scintillation cocktail OptiPhase HiSafe3 (PerkinElmer Wallac, Turkku, Finland). With a standard sample counting time of 10 min, the limit of detection was 7 cpm, corresponding to 57 ng eq/ml in plasma. Late plasma samples were counted for 60 min, resulting in a limit of detection of 2.4 cpm or 9 ng eq/ml.

Radioactivity Analysis of Collected HPLC Fractions. For each HPLC analysis, fractions were collected either directly on solid scintillator-coated microplates (Deepwell LumaPlate-96 or LumaPlate-96; PerkinElmer Life and Analytical Sciences) for off-line radioactivity detection using a microplate scintillation counter (TopCount NXT; PerkinElmer Life and Analytical Sciences) or on polypropylene Deepwell microplates (Porvair Sciences Ltd., Shepperton, UK) followed by transfer of aliquots onto LumaPlates-96 (Boernsen et al., 2000, 2001). The counting time of each fraction was 20 min (triplicates to identify false radioactivity due to electrostatic discharge).

The background counting values of the 12 individual detector heads were measured using an empty Deepwell LumaPlate-96. The measurements of the HPLC fractions, collected on LumaPlate-96, were corrected by subtracting the background value of the corresponding detector head and adding again the average background value of the 12 detector heads (1.7 ± 0.2 cpm, mean ± S.D.) using Microsoft Excel.

Sample Preparation of Plasma, Urine, and Feces for Metabolite Investigation. Semiquantitative determination of main and trace metabolites by radio-HPLC with off-line microplate solid scintillation counting and structural characterization by LC-MS was performed in plasma, urine, and feces pooled over four subjects. Sample pooling over subjects was time-saving and adequate, because metabolite patterns preliminarily observed in plasma of individual subjects at 2, 8, and 24 h were very similar.

View larger version (20K): [in this window] [in a new window]   FIG. 1. Plasma concentrations of total 14C radioactivity, imatinib, and CGP74588 as indicated. A, a linear scale. B, semilogarithmic scale. Error bars represent ± S.D., n = 4.

HPLC Instrumentation for Metabolite Pattern Analysis (Radio-HPLC). HPLC method 1 (used for analysis of plasma and urine): equipment 1. The HPLC system consisted of two HPLC pumps, PU-980 (Jasco, Tokyo, Japan) and an autosampler (AS Jasco AS-950-10). Sample injection was performed through a 2000-µl stainless steel sample loop. The chromatogram was monitored by UV detection at a wavelength of 270 nm using a UV-970M detector (Jasco). The software used was Jasco-Borwin, version 1.50 (Omnilab AG, Mettmenstetten Switzerland). For profiling of metabolite patterns, samples were analyzed on a 4.6 x 150-mm Symmetry C₁₈ column (3.5-µm particle size; Waters, Milford, MA), protected by a Symmetry C₁₈ precolumn (5-µm particle size, 3.9 x 20 mm; Waters), and thermostated at 10°C. The components were eluted with a gradient of formic acid [2% (v/v) in water, pH 2.5; mobile phase A] versus acetonitrile (mobile phase B) at a flow rate of 0.8 ml/min. HPLC fractions were collected for off-line radioactivity detection using a Gilson FC 204 fraction collector (Gilson, Villier Le Bel, France).

HPLC method 2 (used for analysis of feces extracts): equipment 2. The HPLC system consisted of two HPLC pumps (model 420; Kontron Instruments, Watford, Herts, UK) and an HPLC autosampler (model 465; Kontron). Samples were injected through a 2000-µl stainless steel sample loop. Chromatography was monitored by UV detection by a UV HPLC detector model 430 (Kontron) equipped with MT450 software (Kontron). The chromatography conditions were identical for HPLC methods 1 and 2.

Evaluation of HPLC Data. Plasma, urine, or feces extract samples were injected onto the HPLC system, and fractions were collected on Deepwell LumaPlates-96 (fraction volume: 0.16 ml; 12 s/fraction). For each matrix, the recovery from the HPLC column was determined by collection of the total eluent into one flask. An aliquot of the eluent was taken for ¹⁴C measurement by LSC. The amounts of metabolites or parent drug in plasma or excreta were derived from the radiochromatograms (metabolite patterns) by dividing the radioactivity eluting from the HPLC column (equal to radioactivity in original sample minus losses during sample preparation and chromatography) in proportion to the relative peak areas. Parent drug or metabolites were expressed as concentrations (in micromolar) in plasma or as percentage of dose in excreta. These values are to be considered as semiquantitative only, as opposed to those determined by the validated quantitative LC-MS assay (Bakhtiar et al., 2002).

Structural Characterization of Metabolites by LC-MS. Metabolites of [¹⁴C]imatinib were characterized by LC-MS following their isolation from plasma collected at 2 h, urine collected between 0 and 72 h, and feces collected between 0 and 48 h (pools of three or four subjects). The isolated metabolites were injected onto a 4 x 3-mm Polar-RP trapping column (Phenomenex, Torrance, CA), which, after rinsing with water, was connected in a backflush mode to a 150 x 1.0-mm Symmetry C₁₈ analytical column packed with 3.5-µm particles and thermostated at 40°C. The components were eluted with a gradient of aqueous 5 mM ammonium acetate/5 mM acetic acid (mobile phase A) versus acetonitrile (mobile phase B) at a total flow rate of 60 µl/min. For hydrogen-deuterium exchange experiments, the water of the mobile phase A was replaced by D₂O (99.9 atom % D; Cambridge Isotope Laboratories, Andover, MA). The HPLC effluent was split in a ratio of approximately 1:5. The smaller part of the effluent (approximately 10 µl/min) was directed into the electrospray LC-MS interface (Z-spray interface with LockSpray option) of a Micromass Q-Tof 2 hybrid quadrupole time-of-flight tandem mass spectrometer (Micromass UK Ltd, Wythenshawe, UK). The remaining effluent was used for radioactivity monitoring by off-line solid scintillation counting after fraction collection. The electrospray interface was operated with nitrogen as nebulizer gas, as desolvation gas (350 l/h), and as cone gas (40 l/h). The desolvation temperature was set to 150°C, the source block was heated to 80°C, and the spray capillary was set to 3.0 kV. Positive ion single-stage mass spectra were recorded after mass separation by the time-of-flight analyzer. The mass resolution was set to approximately 8000 (full-width at half-maximum definition). The cone voltage was switched repetitively between 30, 40, and 80 V. The M+H⁺ ion of reserpine at m/z 609.2812 was used as lock mass for recalibrating the spectra to obtain exact mass data.

Pharmacokinetic Evaluation. Descriptive statistics of pharmacokinetic parameters include mean ± S.D. Pharmacokinetic parameters were determined through noncompartmental method(s) using Microsoft Excel. A weighted linear regression method was used to calculate the "Slope b" and "Intercept a" of the regression line. A weighting factor of w = 1/y was chosen. The apparent terminal half-life (t_1/2z) was determined from the slope of the regression line of ln(C_t) versus time t. The AUC_0-tn was calculated up to a concentration value of C_n at the last time point, t_n, by the linear-logarithmic trapezoidal method. The AUC was extrapolated to infinite time using the relationship AUC_tn- = (C_n x t_1/2z)/ln(2). The apparent systemic clearance CL/f and apparent terminal volume of distribution V_z/f were calculated as Dose/AUC and (CL/f) x t_1/2z/ln(2), respectively. Factor f means the systemic bioavailability of the drug. The systemic clearance in blood was calculated by CL_Blood = CL_Plasma x F_plasma/(1 - HCT), where HCT indicates the hematocrit value, and F_Plasma = (C_Plasma/C_Blood) x (1 - HCT) means the fraction of imatinib in the plasma compartment obtained from an in vitro blood distribution study in human volunteers (Kretz et al., 2004).

	Results

Top Abstract Materials and Methods Results Discussion References

 
Pharmacokinetics of Imatinib, CGP74588, and Total Radioactivity. After a single oral dose of a nominal 239 mg of [¹⁴C]imatinib mesylate, the mean maximum plasma levels of radioactivity, imatinib, and its pharmacologically active N-desmethyl metabolite CGP74588 were reached rapidly between 1 and 2 h postdose, suggesting rapid absorption (Fig. 1). The total radioactivity at C_max mainly represented unchanged drug (mean, 92%; range, 86-99%) and CGP74588 (mean, 12%; range, 9-14%). The key pharmacokinetic parameters are summarized in Table 1. Interindividual differences in plasma concentrations and in pharmacokinetic parameters were small. Imatinib accounted for 65% of AUC_{0-24 h} of total radioactivity in plasma and the metabolite CGP74588 accounted for 9%. The remaining proportion was due to a number of minor and trace metabolites of imatinib, as detected by off-line microplate solid-scintillation counting (Top-Count) after HPLC separation. Many of them could be characterized at least partially by LC-MS.

Approximately 23% of the radioactivity in blood was calculated to have been distributed into red blood cells. Thus, imatinib and its metabolites are present largely in the plasma (77%). For comparison, the fraction of unchanged imatinib in plasma of healthy volunteers in vitro was 74% (Kretz et al., 2004).

View larger version (23K): [in this window] [in a new window]   FIG. 2. Mass spectrum of imatinib: electrospray ionization, positive ion mode, upfront collision offset (cone voltage) of 80 V, single-stage mass separation, and background-subtracted. Proposed interpretation of the spectrum agrees with exact mass measurements: differences between measured and calculated masses 2.0 mDa for all interpreted signals.

Metabolite Characterization by LC-MS. Metabolite structures were characterized by LC-MS (data in Table 3) and, where possible, confirmed by comparison of mass spectra and retention times with authentic reference compounds (metabolites AFN911, CGP74588, CGP72383, APG049, CGP71422, and APG050). The proposed partial or complete structures are given in Table 4.

View larger version (21K): [in this window] [in a new window]   FIG. 3. Representative metabolite patterns in plasma at 2 (A) and 24 h (B) after dosing. Plasma samples of four subjects were pooled and extracted before HPLC analysis (Method 1). Chemical structures of metabolites are listed in Table 4.

View larger version (18K): [in this window] [in a new window]   FIG. 4. Metabolite pattern in urine collected between 0 and 72 h after dosing. Urine from four subjects was pooled and centrifuged before HPLC analysis (Method 1). Chemical structures of metabolites are listed in Table 4.

View larger version (23K): [in this window] [in a new window]   FIG. 5. Metabolite pattern in an extract of feces collected between 0 and 168 h after dosing. Feces from four subjects was pooled and extracted before HPLC analysis (Method 2). Chemical structures of metabolites are listed in Table 4.

The metabolites of imatinib predominantly underwent fragmentations analogous to those of the parent drug, which allowed us to localize metabolic changes in the substructures of the parent drug molecule reflected by its charged or neutral mass spectral fragments. The proposed metabolite structures were further supported by exact mass measurements of their M+H⁺ ions and by hydrogen-deuterium exchange data (Table 3). The mass spectra of some of the metabolites showed special features that provided additional structural information as described below.

Metabolites APG050 and APG049 were identified as the 3-oxopiperazine derivatives of imatinib and CGP74588, respectively, by comparison with the corresponding reference compounds. Their mass spectra showed a characteristic water adduct of Fragment E (Table 3), confirmed by exact mass measurement, with an intensity higher than that of Fragment E. M23.7 is proposed to be a glucuronide of APG050, because it showed the same characteristic intensity ratio of Fragment E + H₂O/Fragment E >1. In contrast to APG050, the mass spectrum of the closely related isomeric metabolite M29.6 showed no Fragment E + H₂O. Instead, Fragment E was of particularly high intensity, similar to Fragment A, whereas in the mass spectra of most of the other metabolites, Fragment A was the major and Fragment E was a minor cleavage product. Formation of Fragment E seems to be favored in M29.6 at the expense of Fragment A. This may be explained with the presence of a 4-methyl-2-oxopiperazine substructure in M29.6. The M+H⁺ ion of this metabolite might be protonated preferentially in position 4 of the piperazine ring, as opposed to position 1, necessitating the rearrangement of a hydrogen to cleave neutral 4-methylpiperazin-2-one during the formation of Fragment A. In contrast, the M+H⁺ ion of APG050, similar to that of imatinib and most of its metabolites, can be expected to be protonated to a significant extent in position 1 of the piperazine ring, allowing the loss of a neutral 4-methylpiperazin-2-one (or methylpiperazine or piperazine, respectively) without hydrogen rearrangement. The characteristic high intensity ratio of Fragment E/Fragment A, as well as the absence of Fragment E + H₂O, was also found in the mass spectrum of M28.8, which is proposed to represent N-demethylated M29.6, and in the mass spectra of M27.6 and M25.6, which are proposed to be glucuronides of M29.6 and M28.8, respectively.

From a number of minor metabolites detected in the radiochromatograms of plasma (M20.0b, M21.4, and M26.8; see Fig. 3A), urine (M20.0b, M21.4, M22.8, M23.6, M25.2, and M26.4; see Fig. 4), or feces (M19.8, M21.6, M22.8, M23.6, M24.0, M25.2, M26.4, M26.8, M27.8a, M27.8b, M29.2, M31.0, M39.4, and M39.8; see Fig. 5), only partial structures could be determined. All of them were oxidation products, some glucuronidated. The amide bond of imatinib was intact (uncleaved) in all of these metabolites (U. Pfaar, M. Zollinger, and H.-P. Gschwind, unpublished data).

Metabolism. The metabolite patterns in plasma (Fig. 3), urine (Fig. 4), and feces (Fig. 5) from four healthy male volunteers who were given a single 239-mg oral dose of [¹⁴C]imatinib mesylate indicate that unchanged imatinib and its N-desmethyl metabolite CGP74588 were the most prominent components in all of the investigated matrices.

Based on radio-HPLC of plasma samples, 70% of the plasma [¹⁴C]AUC_{0-24 h} amounted to unchanged imatinib and 9.5% amounted to its N-desmethyl metabolite. These semiquantitative values are agree with those obtained by the validated LC-MS assays (Table 1). Another 11% consisted of at least 11 different metabolites of imatinib, the structures of which could be partially characterized by LC-MS (eight of them in Table 4). They individually ranged between 0.2 and 4% of total [¹⁴C]AUC_{0-24 h}.

In urine collected between 0 and 72 h, about 5 and 1.8% of the dose was accounted for by imatinib and its N-desmethyl metabolite CGP74588, respectively. In feces collected between 0 and 168 h, imatinib and CGP74588 accounted for 23 and 11% of dose, respectively. Metabolites in urine and feces were identified by radio-HPLC combined with microplate solid-scintillation counting and structurally characterized by LC-MS as well as by comparison with authentic reference compounds. A representative metabolite pattern in a 0 to 72-h pool of urine is shown in Fig. 4, and a representative metabolite pattern in a 0 to 168-h pool of feces is shown in Fig. 5.

	Discussion

Top Abstract Materials and Methods Results Discussion References

 
Tolerability. Single oral doses of nominal 239 mg of [¹⁴C]imatinib mesylate administered to four healthy male subjects under fasting conditions were well tolerated without any serious adverse event or discontinuation due to an adverse event.

Absorption. The gastrointestinal absorption of imatinib under fasting conditions was rapid, as concluded from the early C_max values of radioactivity, of imatinib, and of the main metabolite CGP74588, typically at 1.5 h postdose. The extent of absorption could not be assessed in this study. However, in a previous study, the absolute oral bioavailability was determined as >97% (Peng et al., 2004a), indicating complete absorption.

Pharmacokinetics. The mean plasma half-life of imatinib was 13.5 h, confirming previously published data (13.9 ± 5.0 h; Peng et al., 2004a). Total radioactivity (sum of imatinib and/or metabolites) decreased in plasma in a multiexponential manner with a terminal half-life longer than two days. Thus, the terminal half-life of plasma radioactivity suggests some accumulation of metabolites. However, this will occur at low concentration levels and will be due to several minor metabolites, not to any single major metabolite. The pharmacokinetics of unchanged imatinib in repeated dose studies did not change significantly, and steady-state was reached in approximately 1 week (Peng et al., 2004b). The accumulation factor was 1.5 to 3.0, as predicted from single dose pharmacokinetics. Interindividual differences in pharmacokinetics and metabolism were low. Imatinib was the predominant radioactive component in plasma, particularly during the first 24 h, representing approximately 70% of AUC_{0-24 h} radioactivity. The pharmacologically active N-desmethyl metabolite (CGP74588) accounted for another 9%. The systemic exposure to numerous minor and trace metabolites was small. With CL/f of 4.18 (ml/min)/kg (18.9 ± 2.0 l/h) and f 1, the plasma clearance of imatinib was approximately 4.2 (ml/min)/kg. From this value and a fraction in plasma of 74% at a hematocrit of 46% (Kretz et al., 2004), a moderate blood clearance of 5.8 (ml/min)/kg corresponding to 28% of the hepatic blood flow in humans [21 (ml/min)/kg; Davies and Morris, 1993] can be calculated. The apparent volume of distribution V_z/f of imatinib found in the present study (366 ± 19 liters, mean ± S.D.) is in good agreement with the V_z/f data published for oral solution (385 ± 167 liters) and capsule (382 ± 194 liters), and is consistent with the volume of distribution V_z (435 ± 154 liters) obtained after i.v. infusion of 100 mg of imatinib (Peng et al., 2004a).

Metabolism. In the excreta (urine, 0-72 h; feces, 0-168 h), dose fractions of 28 and <13% were recovered in the form of imatinib and the N-desmethyl metabolite, respectively. The remaining proportion represented further oxidized metabolites. Thus, oxidative metabolism is the main clearance mechanism. The metabolic processes are summarized in Fig. 6.

View larger version (21K): [in this window] [in a new window]   FIG. 6. Chemical structure of imatinib and identified metabolic processes in human. The main metabolic pathway was the N-demethylation to CGP74588. For details of chemical structures see Table 4.

Excretion. In the observation period of 7 days, the total recovery of radioactivity in feces and urine was incomplete (mean 80.2%). Individual recoveries ranged from 72.9 to 83.6%. Otherwise, the interindividual pharmacokinetic differences were small. Beyond the planned sample collection period of 7 days, additional feces samples were collected from three subjects from day 9 to 11 to follow the continuing excretion process. An apparent terminal elimination half-life of radioactivity in feces was estimated to approximately 3 weeks. The radioactivity was excreted largely with the feces (67.8% of dose in 11 days). A minor dose proportion was excreted in urine (13.2% in 7 days). Imatinib was the main fecal component (23% of dose). The major proportion of fecal imatinib (approximately 16% of dose) was recovered in the late excretion phase. This amount of imatinib in feces could not represent nonabsorbed drug, because absorption and absolute oral bioavailability of imatinib were shown to be nearly complete (Peng et al., 2004a). The substantial fecal recovery of imatinib may be related 1) to biliary excretion of imatinib and/or 2) to unstable metabolites, which were reconverted back to imatinib in the gut (e.g., N-oxides and/or glucuronides) and/or 3) to imatinib-related components secreted via the gastrointestinal walls bypassing the biliary route. There is evidence or strong indications for all of these processes. Ramalingam et al. (2004) reported that a patient receiving daily oral doses of 300 mg of imatinib excreted 17.7 and 2.1% of the dose as unchanged imatinib and CGP74588, respectively, in 0 to 24-h bile. In addition to biliary elimination, direct secretion of imatinib and/or its metabolites from blood through the gastrointestinal walls was observed in bile duct-cannulated rats after a single intravenous dose of 10 mg/kg (H. Wiegand and U. Pfaar, unpublished data). In these animals, a substantial proportion of drug-related components was excreted with feces, bypassing the biliary route (approximately 18% of dose). In the feces, only traces of the piperazine 4-N-oxide (CGP71422) were detected. The pyridine N-oxide metabolite (CGP72383), which was found in plasma and urine, was absent in feces. These observations are in agreement with the reductive potential of human intestinal bacteria toward N-oxides as reported (el-Mekkawy et al., 1993). Furthermore, microbial deconjugation of O-or N-glucuronides of imatinib and of CGP74588 to parent drug and to the N-desmethyl metabolite, respectively, may have taken place in the intestine (Chourasia and Jain, 2003), because conjugates present in plasma and urine were not detected in feces. The available data from this study do not allow us to assess the extent of the biliary excretion of the glucuronic acid conjugates of imatinib and its metabolites. To investigate this, an analysis of human bile from subjects treated with imatinib would be required. Furthermore, it should be noted that elimination of imatinib and intestinal reconversion of metabolites back to imatinib may all contribute to enterohepatic recirculation and to the slow terminal elimination process.

	Acknowledgments

 
We thank Daniel Pierroz, Margrit Riera, Agnes Holler, Serge Delaborde (Novartis Pharma AG, Preclinical Safety Europe, Biotransformation) for excellent technical work, Dr. Andras Kalman and Rene Lehmann (Isotope Laboratory, Novartis Pharma AG, Basel, Switzerland) for the preparation of the radiolabeled drug, and Dr. Bertrand Sutter (Pharmaceutical Analytical Development, Novartis Pharma AG) for the analytical and pharmaceutical support. We also thank Dr. Jürg Zimmermann and Dr. Paul W. Manley (Novartis Pharma AG, Oncology Research) for synthesis of reference compounds.

	Footnotes

 
Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

doi:10.1124/dmd.105.004283.

ABBREVIATIONS: BCR-ABL, p210 BCR-ABL fusion protein found in patients with chronic myelogenous leukemia; CML, chronic myelogenous leukemia; AUC, area under the concentration time curve; GIST, gastrointestinal stromal tumor(s); HPLC, high performance liquid chromatography; LC-MS, liquid chromatography coupled to mass spectrometry; LSC, liquid scintillation counting; PDGFR, platelet-derived growth factor receptor; radio-HPLC, HPLC coupled to radioactivity detection; CGP74588, N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-piperazin-1-ylmethyl-benzamide; CGP72383, N-4-methyl-3-[4-(1-oxy-pyridin-3-yl)-pyrimidin-2-ylamino]-phenyl}-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; CGP71422, 4-(4-methyl-4-oxy-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide; AFN911, N-[4-hydroxymethyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide; APG050, 4-(4-methyl-3-oxo-piperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-benzamide; APG049, N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(3-oxo-piperazin-1-ylmethyl)-benzamide.

Address correspondence to: Dr. Hans-Peter Gschwind, Exploratory Development/DMPK, Novartis Pharma AG, WKL-135.2.25, CH-4002 Basel, Switzerland. E-mail: hans-peter.gschwind{at}novartis.com

	References

Top Abstract Materials and Methods Results Discussion References

 


Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, and Tse F (2002) High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 768: 325-340.[CrossRef][Medline]

Boernsen KO, Bruin GJM, Pfaar U, and Gross G (2001) A new radioactivity detector for metabolic studies: The microplate scintillation counter for 96-well plates. Abstract No. 43 from the 6th International ISSX Meeting October 7-11, 2001, Munich, Germany. Drug Metab Rev 33 (Suppl 1): 1-274.[CrossRef][Medline]

Boernsen KO, Floeckher JM, and Bruin GJ (2000) Use of a microplate scintillation counter as a radioactivity detector for miniaturized separation techniques in drug metabolism. Anal Chem 72: 3956-3959.[Medline]

Botta L, Gerber H-U, and Schmid K (1985) Measurement of radioactivity in biological experiments, in Drug Fate and Metabolism, Methods and Techniques (Garrett ER and Hirtz JL eds) Vol. 5, pp 99-134, Dekker, New York.

Buchdunger E, O'Reilly T, and Wood J (2002) Pharmacology of imatinib (STI571). Eur J Cancer 38 (Suppl 5): S28-S36.

Chourasia MK and Jain SK (2003) Pharmaceutical approaches to colon-targeted drug delivery systems. J Pharm Pharm Sci 6: 33-66.[Medline]

Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, et al. (2002) Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8: 3034-3038.[Abstract/Free Full Text]

Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10: 1093-1095.

Deininger MW, O'Brien SG, Ford JM, and Druker BJ (2003). Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 21: 1637-1647.[Abstract/Free Full Text]

Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.[Abstract/Free Full Text]

el-Mekkawy S, Meselhy MR, Kawata Y, Kadota S, Hattori M, and Namba T (1993) Metabolism of strychnine N-oxide and brucine N-oxide by human intestinal bacteria. Planta Med 59: 347-350.[Medline]

Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, Liebetanz J, Mestan J, O'Reilly T, Traxler P, Chaudhuri B, et al. (2002) Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol Ther 93: 79-98.[CrossRef][Medline]

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (Wash DC) 279: 577-580.[Abstract/Free Full Text]

Kretz O, Weiss HM, Schumacher MM, and Gross G (2004) In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 58: 212-216.[CrossRef][Medline]

le Coutre P, Kreuzer KA, Pursche S, Bonin M, Leopold T, Baskaynak G, Dorken B, Ehninger G, Ottmann O, Jenke A, et al. (2004) Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 53: 313-323.[CrossRef][Medline]

Nikolova Z, Peng B, Hubert M, Seiberling M, Keller U, Ho YY, Schran H, and Capdeville R (2004) Bioequivalence, safety and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 53: 433-438.[CrossRef][Medline]

O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, et al. (2003a) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004.[Abstract/Free Full Text]

O'Brien SG, Meinhardt P, Bond E, Beck J, Peng B, Dutreix C, Mehring G, Milosavljev S, Huber C, Capdeville R, et al. (2003b) Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 89: 1855-1859.[CrossRef][Medline]

Peng B, Dutreix C, Mehring G, Hayes MJ, Ben-Am M, Seiberling M, Pokorny R, Capdeville R, and Lloyd P (2004a) Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 44: 158-162.[Abstract/Free Full Text]

Peng B, Hayes M, Resta D, Racine-Poon A, Druker BJ, Talpaz M, Sawyers CL, Rosamilia M, Ford J, Lloyd P, et al. (2004b) Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 22: 935-942.[Abstract/Free Full Text]

Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, and Ostman A (2002) Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62: 5476-5484.[Abstract/Free Full Text]

Ramalingam S, Lagattuta TF, Egorin MJ, Hayes MJ, and Ramanathan RK (2004) Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans. Pharmacotherapy 24: 1232-1235.[Medline]

Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, et al. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121.[Abstract/Free Full Text]

Schmidli H, Peng B, Riviere G-J, Capdeville R, Hensely M, Gathmann I, Bolton AE, and Racine-Poon (2005) A population pharmacokinetics of imatinib mesylate in patients with chronic-phase myeloid leukemia: results of a phase III study. Br J Clin Pharmacol 60: 35-44.[CrossRef][Medline]

Tuveson DA and Fletcher JA (2001) Signal transduction pathways in sarcoma as targets for therapeutic intervention. Curr Opin Oncol 13: 249-255.[CrossRef][Medline]

This article has been cited by other articles:

				S. Hu, R. M. Franke, K. K. Filipski, C. Hu, S. J. Orwick, E. A. de Bruijn, H. Burger, S. D. Baker, and A. Sparreboom Interaction of Imatinib with Human Organic Ion Carriers Clin. Cancer Res., May 15, 2008; 14(10): 3141 - 3148. [Abstract] [Full Text] [PDF]

				R. K. Ramanathan, M. J. Egorin, C. H.M. Takimoto, S. C. Remick, J. H. Doroshow, P. A. LoRusso, D. L. Mulkerin, J. L. Grem, A. Hamilton, A. J. Murgo, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group J. Clin. Oncol., February 1, 2008; 26(4): 563 - 569. [Abstract] [Full Text] [PDF]

				J. Gibbons, M. J. Egorin, R. K. Ramanathan, P. Fu, D. L. Mulkerin, S. Shibata, C. H.M. Takimoto, S. Mani, P. A. LoRusso, J. L. Grem, et al. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group J. Clin. Oncol., February 1, 2008; 26(4): 570 - 576. [Abstract] [Full Text] [PDF]

				N. P. van Erp, H. Gelderblom, M. O. Karlsson, J. Li, M. Zhao, J. Ouwerkerk, J. W. Nortier, H.-J. Guchelaar, S. D. Baker, and A. Sparreboom Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib Clin. Cancer Res., December 15, 2007; 13(24): 7394 - 7400. [Abstract] [Full Text] [PDF]

				A. V. Boddy, J. Sludden, M. J. Griffin, C. Garner, J. Kendrick, P. Mistry, C. Dutreix, D. R. Newell, and S. G. O'Brien Pharmacokinetic Investigation of Imatinib Using Accelerator Mass Spectrometry in Patients with Chronic Myeloid Leukemia Clin. Cancer Res., July 15, 2007; 13(14): 4164 - 4169. [Abstract] [Full Text] [PDF]

				J. Li, M. O. Karlsson, J. Brahmer, A. Spitz, M. Zhao, M. Hidalgo, and S. D. Baker CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors J Natl Cancer Inst, December 6, 2006; 98(23): 1714 - 1723. [Abstract] [Full Text] [PDF]

				L. M. Jost, H.-P. Gschwind, T. Jalava, Y. Wang, C. Guenther, C. Souppart, A. Rottmann, K. Denner, F. Waldmeier, G. Gross, et al. Metabolism and Disposition of Vatalanib (PTK787/ZK-222584) in Cancer Patients Drug Metab. Dispos., November 1, 2006; 34(11): 1817 - 1828. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.105.004283v1 33/10/1503    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gschwind, H.-P. Articles by Gross, G. Search for Related Content PubMed PubMed Citation Articles by Gschwind, H.-P. Articles by Gross, G.